Abstract:Background: Vascular Dementia (VaD) refers to dementia caused by cerebrovascular disease and/or reduced blood flow to the brain and is the second most common form of dementia after Alzheimer's disease. We previously found that in middle-aged rats subjected to a multiple microinfarction (MMI) model of VaD, treatment with AV-001, a Tie2 receptor agonist, significantly improves short-term memory, long-term memory, as well as improves preference for social novelty compared to control MMI rats. In this study, we tested the early therapeutic effects of AV-001 on inflammation and glymphatic function in rats subjected to VaD. Methods: Male, middle-aged Wistar rats (10–12 m), subjected to MMI, were randomly assigned to MMI and MMI + AV-001 treatment groups. A sham group was included as reference group. MMI was induced by injecting 800 ± 200, 70–100 μm sized, cholesterol crystals into the internal carotid artery. Animals were treated with AV-001 (1 μg/Kg, i.p.) once daily starting at 24 h after MMI. At 14 days after MMI, inflammatory factor expression was evaluated in cerebrospinal fluid (CSF) and brain. Immunostaining was used to evaluate white matter integrity, perivascular space (PVS) and perivascular Aquaporin-4 (AQP4) expression in the brain. An additional set of rats were prepared to test glymphatic function. At 14 days after MMI, 50 μL of 1% Tetramethylrhodamine (3 kD) and FITC conjugated dextran (500 kD) at 1:1 ratio were injected into the CSF. Rats (4–6/group/time point) were sacrificed at 30 min, 3 h, and 6 h from the start of tracer infusion, and brain coronal sections were imaged using a Laser scanning confocal microscope to evaluate tracer intensities in the brain. Result: Treatment of MMI with AV-001 significantly improves white matter integrity in the corpus callosum at 14 days after MMI. MMI induces significant dilation of the PVS, reduces AQP4 expression and impairs glymphatic function compared to Sham rats. AV-001 treatment significantly reduces PVS, increases perivascular AQP4 expression and improves glymphatic function compared to MMI rats. MMI significantly increases, while AV-001 significantly decreases the expression of inflammatory factors (tumor necrosis factor-α (TNF-α), chemokine ligand 9) and anti-angiogenic factors (endostatin, plasminogen activator inhibitor-1, P-selectin) in CSF. MMI significantly increases, while AV-001 significantly reduces brain tissue expression of endostatin, thrombin, TNF-α, PAI-1, CXCL9, and interleukin-6 (IL-6). Conclusion: AV-001 treatment of MMI significantly reduces PVS dilation and increases perivascular AQP4 expression which may contribute to improved glymphatic function compared to MMI rats. AV-001 treatment significantly reduces inflammatory factor expression in the CSF and brain which may contribute to AV-001 treatment induced improvement in white matter integrity and cognitive function.

Mechanism of Velvet Antler Peptide in Preventing Mild Cognitive Impairment Based on Non-Targeted Metabolomics

Sika Deer Velvet Antler Peptide Exerts Neuroprotective Effect in a Parkinson's Disease Model via Regulating Oxidative Damage and Gut Microbiota

Sika Deer Velvet Antler Peptide Exerts Neuroprotective Effect in a Parkinson’s Disease Model Via Regulating Oxidative Damage and Gut Microbiota

Anti-Alzheimers molecular mechanism of icariin: Insights from gut microbiota and metabolome combined network pharmacology

AVP(4-8) Improves Cognitive Behaviors and Hippocampal Synaptic Plasticity in the APP/PS1 Mouse Model of Alzheimer’s Disease

Early therapeutic effects of an Angiopoietin-1 mimetic peptide in middle-aged rats with vascular dementia

Effects of Velvet Antler Polypeptide on Sexual Behavior and Testosterone Synthesis in Aging Male Mice.

[Protective Effects of Peptides from Velvet Antler of Cervus Nippon on Acute Ischemic Myocardial Injury in Rats].

Effect of Akt-activating peptide obtained from walnut protein degradation on the prevention of memory impairment in mice

Effects of an Akt-activating Peptide Obtained from Walnut Protein Degradation on the Prevention of Memory Impairment in Mice

Treatment of vascular dementia in female rats with AV-001, an Angiopoietin-1 mimetic peptide, improves cognitive function

Proteomic analysis provides insights into the molecular regulatory mechanism of Dengzhan Shengmai capsule in a rat model of vascular dementia

Velvet antler polypeptide (VAP) protects against cerebral ischemic injury through NF-κB signaling pathway in vitro

Protective Effects of Cervus Nippon Temminck Velvet Antler Polypeptides Against Mpp+-Induced Cytotoxicity in Sh-Sy5y Neuroblastoma Cells

Molecular profiling of a rat model of vascular dementia: Evidences from proteomics, metabolomics and experimental validations

The Protective Effect of Vanadium on Cognitive Impairment and the Neuropathology of Alzheimer's Disease in APPSwe/PS1dE9 Mice

A Novel Neuroprotective Peptide YVYAETY Identified and Screened from Flammulina Velutipes Protein Hydrolysates Attenuates Scopolamine-Induced Cognitive Impairment in Mice

Influence of acidic peptide on learning and memory abilities and levels of APP,BACE and tau protein in brains of vascular dementia mice

A Rat Model of Mild Cognitive Impairment Associated with Vascular Factor

Effect of Adiponectin Intervention on Cognitive Function in Rats with Vascular Dementia

Novel neuroprotective peptide YVYAETY identified and screened from Flammulina Velutipes protein hydrolysates attenuates scopolamine-induced cognitive impairment in mice